Humoral Immunity: B Cells, Antibodies, Complement and Clinical Disorders

Humoral immunity is the antibody-mediated arm of adaptive immunity. B lymphocytes recognise antigen, receive activation signals, and differentiate into plasma cells that secrete immunoglobulins. Antibodies act mainly in extracellular fluids and mucosal surfaces by neutralising toxins and viruses, opsonising microbes, activating complement and recruiting immune effector cells. Effective humoral defence depends on B-cell tolerance, T-cell help, germinal-centre maturation and long-lived memory.

Learning outcomes

The learner should be able to describe B-cell development and activation, explain immunoglobulin structure and isotypes, compare T-dependent and T-independent responses, describe antibody effector functions and complement interaction, interpret common serology patterns, and recognise humoral immunodeficiency and emergencies.

1. B-cell development and tolerance

1.1 Development

B-cell precursors arise in bone marrow. Immunoglobulin gene rearrangement generates a unique B-cell receptor (BCR) for each clone. Immature B cells that strongly recognise self may be deleted, edited or rendered anergic. Mature naive B cells express surface IgM and IgD and circulate through lymphoid tissues.

1.2 Central and peripheral tolerance

• Central tolerance: self-reactive immature B cells are deleted, revise their receptor or become unresponsive.
• Peripheral tolerance: lack of T-cell help, inhibitory receptors, regulatory cells and deletion limit autoreactive clones.
• Breakdown can produce autoantibodies, immune-complex disease or antibody-mediated tissue injury.

2. Antigen recognition and B-cell activation

BCRs bind intact, three-dimensional antigen. A B cell internalises the antigen, processes protein fragments and presents them on MHC II. A T follicular helper cell recognises the peptide–MHC II complex and supplies CD40L–CD40 interaction plus cytokines. This “linked recognition” ensures that T-cell help is directed to the same antigen captured by the B cell.

2.1 T-dependent activation

1. Antigen binds the BCR and is internalised.
2. The B cell presents peptide on MHC II.
3. T follicular helper cells provide co-stimulation and cytokines.
4. Activated B cells proliferate and form extrafollicular plasmablasts or germinal centres.
5. Class switching, somatic hypermutation, affinity maturation and memory formation follow.

2.2 T-independent activation

Highly repetitive antigens such as bacterial polysaccharides can cross-link many BCRs and activate B cells with limited T-cell help. The response is rapid but often produces mainly IgM, shorter-lived plasma cells and weaker memory. Conjugate vaccines attach polysaccharide to protein so T-cell help can be recruited, improving infant responses and memory.

3. Germinal-centre reaction

Process	What happens	Clinical value
Somatic hypermutation	Point mutations are introduced into variable-region genes	Creates BCR variants with different affinities
Affinity selection	Higher-affinity clones capture antigen and receive survival signals	Improves antibody binding after infection or vaccination
Class-switch recombination	Constant region changes from IgM/IgD to IgG, IgA or IgE	Changes effector function without changing antigen specificity
Memory formation	Long-lived B cells and plasma cells are generated	Faster response on re-exposure

Activation-induced cytidine deaminase is central to somatic hypermutation and class switching. Defects can cause hyper-IgM syndromes, recurrent infection and poor vaccine responses.

4. Immunoglobulin structure

An antibody contains two identical heavy chains and two identical light chains joined by disulphide bonds. The variable regions form antigen-binding sites; the constant Fc region determines class and interaction with complement or Fc receptors. A flexible hinge allows some antibodies to bind epitopes at different distances.

• Fab region: binds antigen.
• Fc region: recruits complement, phagocytes, NK cells or transport mechanisms.
• Valency: IgG is usually bivalent; secreted IgA is commonly dimeric; IgM is secreted as a pentamer with high avidity.
• Affinity: strength of one antigen-binding site; avidity is total binding strength across multiple sites.

5. Immunoglobulin classes

Class	Structure/distribution	Main functions	Clinical relevance
IgM	Monomer on B cells; pentamer in serum	First response, strong complement activation, agglutination	Early serological marker in some infections; high IgM may indicate recent exposure but is not definitive alone
IgG	Monomer; most abundant serum class; crosses placenta	Neutralisation, opsonisation, complement, ADCC and durable memory	Long-term vaccine/previous-exposure antibody; maternal neonatal protection
IgA	Monomer in serum; secretory dimer at mucosa	Mucosal neutralisation and immune exclusion with limited inflammation	Deficiency predisposes to mucosal infection and transfusion reactions in selected patients
IgE	Low serum concentration; binds mast cells and basophils	Immediate hypersensitivity and helminth defence	Allergy, anaphylaxis and parasitic disease
IgD	Surface receptor on naive B cells; little secreted serum	B-cell activation and mucosal signalling	Limited routine diagnostic use

6. Antibody effector functions

6.1 Neutralisation

Antibody blocks microbial attachment, entry, toxin binding or viral fusion. Neutralisation is often the main protective function against extracellular toxins and viruses.

6.2 Opsonisation

IgG Fc regions and complement fragments coat microbes. Neutrophils and macrophages bind these opsonins through Fc and complement receptors, increasing phagocytosis. Patients lacking antibody or complement are especially vulnerable to encapsulated bacteria.

6.3 Complement activation

Antigen-bound IgM or IgG activates the classical pathway. Complement enhances inflammation, opsonisation and membrane attack. Complement regulators protect host cells from accidental injury.

6.4 Antibody-dependent cellular cytotoxicity

NK cells and other effector cells bind Fc regions on antibody-coated targets and release cytotoxic mediators. This bridges humoral recognition to cellular killing.

6.5 Agglutination and precipitation

Multivalent antibodies cross-link particles or soluble antigens, making them easier to clear. IgM is particularly effective because of its pentameric structure.

7. Mucosal humoral immunity

Secretory IgA is produced by plasma cells beneath mucosal epithelium. It is transported across epithelial cells and released with a secretory component that protects it from proteases. IgA neutralises pathogens and toxins without strongly activating complement, reducing collateral tissue injury in the gut, airway and genitourinary tract.

Breast milk provides secretory IgA and other factors that support infant mucosal defence. Mucosal vaccination aims to generate local antibody and tissue-resident immune protection where pathogens enter.

8. Antibody kinetics and memory

During a primary response, IgM usually appears first, followed by class-switched antibody. On repeat exposure, memory B cells rapidly generate higher-affinity IgG, IgA or IgE depending on the tissue and cytokine environment. Long-lived plasma cells can maintain antibody even when antigen is no longer present.

• Antibody levels may decline while memory persists.
• Antibody presence does not always mean sterilising immunity.
• Antigenic variation can allow reinfection despite previous antibodies.
• Immunosuppression can reduce both antibody production and memory formation.

9. Interpreting serology

Finding	Possible interpretation	Important caution
IgM positive	Recent response in some infections	Cross-reactivity, persistent IgM or false positives occur
IgG positive	Past infection, vaccination or later response	Does not necessarily prove current infection or protection
Seroconversion	Change from negative to positive in paired samples	Timing and validated assay are essential
Fourfold titre rise	Supports recent infection in selected paired-serology protocols	Not universally applicable
Low/absent antibody	No exposure, early testing or impaired humoral response	Consider direct pathogen tests and repeat testing

Always interpret serology with symptoms, exposure, vaccination history, immune status, local epidemiology and test performance. In emergencies, treatment should not wait for antibody results.

10. Humoral immunodeficiency

10.1 Primary disorders

• X-linked agammaglobulinaemia: impaired B-cell maturation and very low immunoglobulins; recurrent bacterial and enteroviral infection after maternal IgG wanes.
• Common variable immunodeficiency: low immunoglobulins and impaired antibody responses with recurrent respiratory infection, autoimmunity or lymphoproliferation.
• Selective IgA deficiency: often asymptomatic but may cause mucosal infection, allergy or transfusion reactions.
• Hyper-IgM syndromes: impaired class switching with low IgG/IgA and recurrent/opportunistic infection.

10.2 Secondary disorders

HIV, protein loss, nephrotic syndrome, gastrointestinal loss, haematological malignancy, malnutrition, splenectomy, chemotherapy, corticosteroids and B-cell-depleting medicines can reduce antibody protection.

10.3 Clinical pattern

Think of humoral deficiency with recurrent otitis, sinusitis, pneumonia, sepsis, infection by encapsulated bacteria, poor vaccine responses or chronic enterovirus/giardia. Document infection frequency, organisms, hospitalisations, family history and immunisation response.

11. Humoral autoimmunity and immune complexes

Autoantibodies can block receptors, stimulate receptors, destroy cells or form immune complexes. Complexes deposit in vessels, glomeruli, joints and skin, activate complement and cause inflammation. Examples include autoimmune haemolytic anaemia, Graves disease, myasthenia gravis, systemic lupus and vasculitis.

12. Therapeutic antibodies and passive protection

Immunoglobulin preparations and monoclonal antibodies provide passive or targeted protection. They may neutralise toxins, block cytokines, deplete B cells, inhibit tumour pathways or prevent viral entry. Risks include infusion reactions, allergy, infection susceptibility, thrombosis or organ-specific toxicity depending on the product. Follow product-specific guidance and monitor the patient.

13. Vaccines and conjugate design

Protein antigens usually generate T-dependent, class-switched memory. Plain polysaccharide vaccines can produce weaker responses in young children. Conjugating polysaccharide to a protein carrier recruits T-cell help and improves memory. Adjuvants enhance innate signals and antigen presentation.

14. Emergency applications

15. Cases

Case 1: Recurrent pneumonia

An adult has frequent bacterial sinusitis and pneumonia with poor vaccine response. Assess quantitative immunoglobulins, specific antibody responses, protein loss, HIV and haematological disease, then refer to immunology.

Case 2: Suspected recent infection

A patient has a positive IgM but no compatible symptoms and a negative confirmatory test. Do not label the patient infected from IgM alone; investigate cross-reactivity, timing and alternative diagnoses.

Case 3: Infant after maternal antibodies decline

An infant who was initially well develops recurrent bacterial infections after several months. Maternal IgG has waned, revealing an underlying antibody-production disorder. Urgent infection management comes before immunology testing.

16. Exam pearls

• B cells recognise native antigen; T cells recognise processed peptide on MHC.
• IgM is usually first and activates complement effectively; IgG is the major systemic memory antibody; IgA protects mucosa; IgE mediates allergy and helminth defence.
• Class switching changes Fc function, not antigen specificity.
• Affinity maturation improves binding through germinal-centre selection.
• Antibodies neutralise, opsonise, activate complement and recruit cytotoxic effector cells.
• Low immunoglobulin plus recurrent encapsulated-bacterial infection suggests humoral immunodeficiency.

References and further reading

• NCBI Bookshelf: The humoral immune response.
• NCBI Bookshelf: B cells and antibodies.
• NCBI Bookshelf: Immunoglobulins.
• NIAID: Primary immunodeficiency diseases.
• Follow local immunisation, transfusion, sepsis, anaphylaxis and immunology protocols.